Keyes Stange & Wooten Wealth Management LLC Takes Position in IQVIA Holdings Inc. (NYSE:IQV)

Keyes Stange & Wooten Wealth Management LLC acquired a new stake in shares of IQVIA Holdings Inc. (NYSE:IQV) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 844 shares of the medical research company’s stock, valued at approximately $200,000.

Other institutional investors and hedge funds have also bought and sold shares of the company. Versant Capital Management Inc grew its holdings in shares of IQVIA by 733.3% during the second quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after buying an additional 110 shares during the last quarter. Opal Wealth Advisors LLC bought a new stake in shares of IQVIA in the 2nd quarter worth $27,000. Capital Performance Advisors LLP purchased a new position in shares of IQVIA in the third quarter worth $27,000. Park Place Capital Corp bought a new position in shares of IQVIA during the third quarter valued at $28,000. Finally, Itau Unibanco Holding S.A. bought a new stake in IQVIA in the 2nd quarter worth about $29,000. 89.62% of the stock is currently owned by institutional investors.

IQVIA Stock Up 2.1 %

IQV opened at $201.82 on Friday. IQVIA Holdings Inc. has a fifty-two week low of $187.62 and a fifty-two week high of $261.73. The company has a debt-to-equity ratio of 1.76, a quick ratio of 0.81 and a current ratio of 0.81. The stock has a market cap of $36.63 billion, a price-to-earnings ratio of 26.49, a price-to-earnings-growth ratio of 2.03 and a beta of 1.51. The firm’s fifty day moving average is $222.67 and its 200 day moving average is $227.18.

Analyst Upgrades and Downgrades

Several equities analysts have issued reports on the stock. Truist Financial lowered their target price on shares of IQVIA from $286.00 to $265.00 and set a “buy” rating on the stock in a research note on Monday, November 4th. JPMorgan Chase & Co. dropped their target price on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a report on Tuesday, November 5th. Redburn Atlantic initiated coverage on shares of IQVIA in a research note on Monday, October 14th. They set a “buy” rating and a $276.00 target price for the company. Argus upgraded IQVIA to a “strong-buy” rating in a research note on Wednesday, July 31st. Finally, BTIG Research lowered their target price on IQVIA from $290.00 to $260.00 and set a “buy” rating on the stock in a report on Friday, November 1st. Four equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, IQVIA presently has an average rating of “Moderate Buy” and a consensus target price of $256.50.

Insider Activity

In other news, insider Eric Sherbet sold 1,300 shares of IQVIA stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the sale, the insider now owns 19,536 shares in the company, valued at $4,812,302.88. This trade represents a 6.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 1.60% of the company’s stock.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.